An international team led by researchers at Concordia University has identified a specific pattern of brain activity during deep sleep that appears to shield the aging brain from a chemical linked to Alzheimer's progression. People whose brains produced stronger slow oscillations and sleep spindles at night had less cognitive decline over three years, even when a wakefulness-linked neurotransmitter called orexin was high.
The prospective cohort study followed 60 adults with mild to moderate Alzheimer's disease, average age 74.7, at Universitat de Lleida in Catalonia, Spain. Each participant underwent overnight sleep recordings, cerebrospinal fluid sampling and repeated cognitive assessments. Findings from the group were published in Neurology on August 25, 2026.
What the researchers actually measured
Orexin is a neurotransmitter that helps regulate wakefulness, appetite and the transition into sleep. In the study, participants with higher orexin levels in their cerebrospinal fluid showed faster cognitive decline, worse memory and thinking scores, more neuropsychiatric symptoms and higher biological markers of neurodegeneration.
The surprise came from what happened during non-REM sleep. Individuals who generated stronger sleep spindles, brief bursts of brain activity, and slow oscillations, the slow rolling waves that dominate the deepest stage of sleep, appeared to be protected from those effects. Their cognitive scores held up better than those of peers with weaker deep-sleep activity.
Also read: Dietitians point to this snack to boost your brain health
"This study shows that there is a direct association between orexin levels in the brain and biomarkers of Alzheimer's disease," said Thanh Dang-Vu, a neurologist at Concordia and senior author on the paper, in a statement summarizing the research. He added that "just as too little orexin is associated with diseases like narcolepsy, too much orexin can lead to higher vulnerability of Alzheimer's."
Why deep sleep matters for the aging brain
Deep, non-REM sleep is when the brain's waste-clearance machinery works hardest. Human studies have shown that the glymphatic system, a network of channels around blood vessels, flushes proteins including amyloid beta and tau, both hallmarks of Alzheimer's, out of brain tissue during sleep. A 2026 Nature Communications study in 39 adults found that morning plasma levels of these Alzheimer's biomarkers rose after normal sleep compared with a night of sleep deprivation, evidence that clearance is genuinely sleep dependent.
That backdrop helps explain why the depth and structure of sleep, not just its length, may matter for brain aging. Earlier work from our archive has shown that subtle changes in sleep can signal Alzheimer's years before memory problems appear, and that total hours in bed alone do not guarantee restorative deep sleep.
What it could mean for treatment
The new findings do not prove that boosting deep sleep will slow Alzheimer's. This was an observational study of 60 people with existing disease, not a randomized trial, so the results show association rather than cause. Larger trials will be needed to test whether interventions that increase spindles or slow oscillations translate into slower decline.
Also read: 7 warning signs of esophageal cancer that are easy to write off as heartburn
Drugs that block orexin receptors are already approved for insomnia. Merck's suvorexant, sold as Belsomra, received an FDA label update in 2020 to include data from a study of patients with mild to moderate Alzheimer's disease and insomnia. Whether these medications can also alter the trajectory of the disease itself is still being investigated in clinical research.
Alzheimer's affects an estimated 7.4 million Americans age 65 and older, according to the Alzheimer's Association's 2026 facts and figures. Anyone worried about memory changes or persistent sleep problems should talk with a doctor, who can evaluate whether a sleep study or cognitive assessment is warranted.
Also read: This new treatment might cure type 1 diabetes
This article is made and published by Emil Martesen, who may have used AI in the preparation.